Integra LifeSciences posts third-quarter revenue of $411.2 million
- Integra LifeSciences (NASDAQ:IART) reported third-quarter 2026 revenue of $411.2 million, up 2.3% year over year despite an estimated $7 million impact from flooding at its Cincinnati manufacturing facility.
- GAAP diluted EPS improved to $0.19 from a loss of $0.07, while adjusted EPS rose to $0.59 from $0.54 and quarterly operating cash flow reached $96 million.
- Integra completed approximately $2.1 billion in refinancing transactions on October 19 and maintained its revised annual revenue guidance of $1.634 billion–$1.654 billion and adjusted EPS outlook of $2.30–$2.40.
Integra LifeSciences (NASDAQ:IART) reported third-quarter 2026 revenue of $411.2 million, up 2.3% year over year despite supply disruptions at its Cincinnati manufacturing facility.
Organic revenue increased 2.5%, while GAAP diluted earnings improved to $0.19 per share from a loss of $0.07 in the prior-year quarter.
Adjusted diluted earnings increased to $0.59 from $0.54, although gross margin narrowed to 51.0% from 51.5%, reflecting continued operating pressures.
Specialty Surgery revenue increased 3.9%, while Tissue Reconstruction sales declined 2.2%, with the July flooding estimated to have reduced quarterly revenue by approximately $7 million.
Integra maintained its 2026 revenue guidance of $1.634 billion–$1.654 billion and adjusted EPS forecast of $2.30–$2.40, while anticipating lower fourth-quarter reported revenue.
Operating cash flow reached $96 million and consolidated total leverage declined to 3.8 times, while an October 19 refinancing extended the company's debt maturities.
The company expects Cincinnati manufacturing operations to fully recover during the second quarter of 2027, with ongoing restoration efforts intended to improve product availability.
